Financing
Medtech funding in 2025 sees a trend of fewer, yet larger deals with total funding of $3.6bn in Q1, $2.6bn in Q2 and $2.9bn in Q3, said LSI’s Nick Talamantes. In 2026, he expects a continued investor focus on more mature firms in areas of oncology, cardiology and neurology.
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.
The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.
Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.
Jupiter Endovascular is positioning Vertex as a next-generation pulmonary thrombectomy solution that could redefine procedural standards, especially if ongoing SPIRARE trials confirm its clinical advantages.
J&J announced the separation of its orthopedics unit into a stand-alone company. The firm as a whole expects sales growth of over 5% in 2026. Gabelli analyst Jennie Tsai foresees more consolidation in orthopedics led by Zimmer Biomet, Stryker and DePuy as well as more acquisitions.
Family offices, impact funds, and public-private partnerships are among alternative approaches to financing that stress early-stage investment, collaboration, impact and health equity – but not, at least for family practices, AI.
Confido Health has raised $10m in Series A funding to expand its AI voice agent from patient scheduling into referrals, prescriptions and billing, bringing the total collected to $13m. CEO Chetan Reddy predicts in the next decade, AI use for admin tasks in healthcare will become mainstream.
While Sunrise’s main differentiator is a sensor that detects movement of the lower jaw, the company’s growth plan leans heavily on artificial intelligence to make care scalable. In practice, that means AI handles data triage, therapy monitoring and adherence support.
Sonomind’s immediate focus is treatment-resistant depression, but the company sees broader applications for its platform to treat psychiatric conditions such as anxiety, post-traumatic stress disorder and addiction.
Sava Technologies has developed a CGM that uses microneedles to accurately measure glucose levels for up to 10 days without finger-prick calibration. The company raised £14.2m in Series A funding to establish in-house manufacturing for faster production.
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
Galvanize will use its $100m Series C funding to expand commercial operations and advance Aliya PEF in oncology and RheOx in chronic bronchitis, while continuing to refine its nonthermal PEF platform, which delivers short electrical pulses to disrupt disease processes.
Ketryx relies on a combination of continuous validation, testing, and human oversight to ensure the platform remains compliant and reliable as AI capabilities evolve, CEO Kaminski said.
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.
With $7.6m in funding, Qbeast plans to allocate about 55% of resources to engineering and R&D, 25% to go-to-market partnerships, sales, and marketing, 10% to customer success and onboarding and the remaining 10% to internal platform and operations to support scaling.
Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.
Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.